In agreement with our results, the analysis of cancer patients’ samples show that, as expected, shmt2 expression gradually increases during the various stages of disease progression, while shmt1 expression increases only in the more advanced stages; moreover, shmt1 expression nicely correlates with that of the transporters involved in this work. This evidence concerns the gene SHMT2 and cancer.